Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK/PD of UPB-101 in Adults with Asthma
NCT05448651Phase 1Completed
- Sponsor
- Upstream Bio
- Start
- Jul 2022
- Primary completion
- Aug 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vereckitug in asthma (4 cohorts), sponsored by Upstream Bio. Primary endpoint: Number of Treatment-emergent Adverse Events and Serious Adverse Events at 24 weeks. Started Jul 2022; status: completed.
02
Drugs
vereckitug
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05448651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05448651.